[The possibilities and prospects in using the calcium antagonist korinfar in patients with bronchial asthma].
A study of patients with a stable course of bronchial asthma (BA) has confirmed the absence of a significant bronchodilating effect of nifedipine during an acute drug test (a single sublingual administration of the drug at a dose of 20 mg). Preliminary administration of nifedipine at a dose of 20 mg was noted to result in the prolongation of a bronchodilating effect of salbutamol inhaled at a dose of 200 micrograms, not influencing a degree of its expression. it has been assumed that prolonged use of nifedipine would result in reduced requirements of BA patients in inhalation sympathomimetics. This therapeutic trend especially holds promise for middle aged and aged BA patients with concomitant CHD, arterial hypertension. Reduced requirements in sympathomimetics in them would lead to the reduction of risk of iatrogenic exacerbations of cardiovascular diseases.
Sinopal'nikov
A I
AI
Efimov
A V
AV
Alekseev
V G
VG
D000280:Administration, Inhalation; D000368:Aged; D000420:Albuterol / Q000008:administration & dosage; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D001985:Bronchial Provocation Tests; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006801:Humans; D008875:Middle Aged; D009543:Nifedipine / Q000627:therapeutic use*; D012119:Respiration / Q000187:drug effects; D013997:Time Factors
D002121:Calcium Channel Blockers; D009543:Nifedipine; D000420:Albuterol
Vozmozhnosti i perspektivy primeneniia antagonista kal'tsiia korinfara u bol'nykh bronkhial'noĭ astmoĭ.